TKNO Q1 2025 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$10M+5.4% YoY

Gross Profit

$3M30.7% margin

Operating Income

-$5M-50.7% margin

Net Income

-$5M-47.4% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+5.7%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$852,000

Balance Sheet

Total Assets

$114M

Total Liabilities

$35M

Stockholders' Equity

$79M

Cash & Equivalents

$3M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$9M	+5.4%
Gross Profit	$3M	$2M	+36.1%
Operating Income	-$5M	-$8M	+37.8%
Net Income	-$5M	-$8M	+42.6%

Revenue Segments

Lab Essentials

$8M83%

Clinical Solutions

$1M12%

Other Product

$516,0005%

Geographic Segments

UNITED STATES

$9M95%

Non-US

$523,0005%